Amanda Aparecida Maia Neves Garcia, Juliana Aenishanslin, Carolina Yoshi Campos Sugio, Thais Letícia Moreira da Silva, Vanessa Migliorini Urban, Marina Tolentino Marinho, Benjamim de Melo Carvalho, Karin Hermana Neppelenbroek, Priscileila Colerato Ferrari
{"title":"制霉菌素：β-环糊精和氯己定：β-环糊精黏附水凝胶用于特定部位的口腔应用。","authors":"Amanda Aparecida Maia Neves Garcia, Juliana Aenishanslin, Carolina Yoshi Campos Sugio, Thais Letícia Moreira da Silva, Vanessa Migliorini Urban, Marina Tolentino Marinho, Benjamim de Melo Carvalho, Karin Hermana Neppelenbroek, Priscileila Colerato Ferrari","doi":"10.1080/20415990.2025.2467018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop and analyze nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels.</p><p><strong>Materials & methods: </strong>Hydrogels were characterized by <i>in vitro</i> and <i>ex vivo</i> analyses, and antifungal activity against <i>Candida albicans</i>.</p><p><strong>Results: </strong>The hydrogel showed high adhesiveness and retention (83.37 ± 2.05%) to the porcine oral mucosa. The drug release from complexed nystatin and chlorhexidine hydrogels was 1.5 (95 µg/cm<sup>2</sup>) and 4.0 times higher (800 µg/cm<sup>2</sup>) than non-complexed drugs. Rheological studies indicated the prevalence of elastic behavior of the formulations. <i>Ex vivo</i> permeation using porcine mucosa showed retention on the oral mucosa. Hydrogels with nystatin and chlorhexidine inclusion complex showed inhibition percentages of 88.87% and 91.57%, respectively, and median inhibition zones of 8 mm.</p><p><strong>Conclusion: </strong>Mucoadhesive hydrogels with inclusion complex are promising for oral lesions with greater retention at the treatment site.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"327-338"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970780/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels for site-specific buccal applications.\",\"authors\":\"Amanda Aparecida Maia Neves Garcia, Juliana Aenishanslin, Carolina Yoshi Campos Sugio, Thais Letícia Moreira da Silva, Vanessa Migliorini Urban, Marina Tolentino Marinho, Benjamim de Melo Carvalho, Karin Hermana Neppelenbroek, Priscileila Colerato Ferrari\",\"doi\":\"10.1080/20415990.2025.2467018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study aimed to develop and analyze nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels.</p><p><strong>Materials & methods: </strong>Hydrogels were characterized by <i>in vitro</i> and <i>ex vivo</i> analyses, and antifungal activity against <i>Candida albicans</i>.</p><p><strong>Results: </strong>The hydrogel showed high adhesiveness and retention (83.37 ± 2.05%) to the porcine oral mucosa. The drug release from complexed nystatin and chlorhexidine hydrogels was 1.5 (95 µg/cm<sup>2</sup>) and 4.0 times higher (800 µg/cm<sup>2</sup>) than non-complexed drugs. Rheological studies indicated the prevalence of elastic behavior of the formulations. <i>Ex vivo</i> permeation using porcine mucosa showed retention on the oral mucosa. Hydrogels with nystatin and chlorhexidine inclusion complex showed inhibition percentages of 88.87% and 91.57%, respectively, and median inhibition zones of 8 mm.</p><p><strong>Conclusion: </strong>Mucoadhesive hydrogels with inclusion complex are promising for oral lesions with greater retention at the treatment site.</p>\",\"PeriodicalId\":22959,\"journal\":{\"name\":\"Therapeutic delivery\",\"volume\":\" \",\"pages\":\"327-338\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970780/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic delivery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/20415990.2025.2467018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2025.2467018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels for site-specific buccal applications.
Background: This study aimed to develop and analyze nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels.
Materials & methods: Hydrogels were characterized by in vitro and ex vivo analyses, and antifungal activity against Candida albicans.
Results: The hydrogel showed high adhesiveness and retention (83.37 ± 2.05%) to the porcine oral mucosa. The drug release from complexed nystatin and chlorhexidine hydrogels was 1.5 (95 µg/cm2) and 4.0 times higher (800 µg/cm2) than non-complexed drugs. Rheological studies indicated the prevalence of elastic behavior of the formulations. Ex vivo permeation using porcine mucosa showed retention on the oral mucosa. Hydrogels with nystatin and chlorhexidine inclusion complex showed inhibition percentages of 88.87% and 91.57%, respectively, and median inhibition zones of 8 mm.
Conclusion: Mucoadhesive hydrogels with inclusion complex are promising for oral lesions with greater retention at the treatment site.
期刊介绍：
Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
